| Autor: |
Dugonjić Okroša, A., Silovski, T., Dedić Plavetić, N., Mucalo, I. |
| Přispěvatelé: |
Mršić-Pelčić, J., Vitezić, D., Janković, T. |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
Introduction High survival rate in early breast cancer is a direct consequence of highly effective adjuvant endocrine treatment (AET) recommended to be taken 5 to 10 years. However, AET has numerous side effects that adversely affect the quality of life (QoL) and preclude long-term adherence. This study aimed to investigate the Qo Linearly-stage breast cancer in women receiving AET and to explore its association with adherence. Materials and methods This cross-sectional study included women with early hormone-dependent breast cancer treated with AET for more than 3 months. There search was conducted at the University Hospital Centre (UHC) Zagreb. Validated instruments, the Medication Adherence Report scale(MARS-5) and the Functional Assessment of Cancer Therapy, endocrine symptoms- FACT-ES, were used. The collected data were processed and presented with descriptive statistics and an independentt-test. Results Overall, 329 respondents completed the survey. In line with the MARS score participants were divided into 4 groups: 56.3% of adherers (taking all indicated doses), unintentional non- adherers(26.3%), intentionalnon-adherers(3.9%) andintentional/unintentionalnon-adherers(13.5%). Total QoL score was generally high (score range 138-146 out of 184) and not significantly different between the groups (t-test, p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
